Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) EBIT: 2019-2024

Historic EBIT for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to -$261.6 million.

  • Kymera Therapeutics' EBIT fell 28.28% to -$92.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$332.3 million, marking a year-over-year decrease of 65.97%. This contributed to the annual value of -$261.6 million for FY2024, which is 58.06% down from last year.
  • Per Kymera Therapeutics' latest filing, its EBIT stood at -$261.6 million for FY2024, which was down 58.06% from -$165.5 million recorded in FY2023.
  • In the past 5 years, Kymera Therapeutics' EBIT registered a high of -$46.3 million during FY2020, and its lowest value of -$261.6 million during FY2024.
  • Moreover, its 3-year median value for EBIT was -$165.5 million (2023), whereas its average is -$196.1 million.
  • Data for Kymera Therapeutics' EBIT shows a maximum YoY plummeted of 117.11% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Kymera Therapeutics' EBIT stood at -$46.3 million in 2020, then slumped by 117.11% to -$100.5 million in 2021, then plummeted by 60.41% to -$161.3 million in 2022, then declined by 2.65% to -$165.5 million in 2023, then plummeted by 58.06% to -$261.6 million in 2024.